Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injury — United States, November 2019

Kevin Chatham-Stephens, MD; Katherine Roguski, MPH; Yunho Jang, PhD; Pyone Cho, MD; Tara C. Jatlaoui, MD; Sarah Kabbani, MD; Emily Glidden, MPH; Emily N. Ussery, PhD; Katrina F. Trivers, PhD; Mary E. Evans, MD; Brian A. King, PhD; Dale A. Rose, PhD; Christopher M. Jones, PharmD, DrPH; Grant Baldwin, PhD; Lisa J. Delaney, MS; Peter Briss, MD; Matthew D. Ritchey, DPT; Lung Injury Response Epidemiology/Surveillance Task Force; Lung Injury Response Clinical Task Force

On November 19, 2019, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr).

CDC, the Food and Drug Administration (FDA), state and local health departments, and public health and clinical stakeholders are investigating a nationwide outbreak of e-cigarette, or vaping, product use–associated lung injury (EVALI) (1). As of November 13, 2019, 49 states, the District of Columbia, and two U.S. territories (Puerto Rico and U.S. Virgin Islands) have reported 2,172 EVALI cases to CDC, including 42 (1.9%) EVALI-associated deaths. To inform EVALI surveillance, including during the 2019–20 influenza season, case report information supplied by states for hospitalized and nonhospitalized patients with EVALI were analyzed using data collected as of November 5, 2019. Among 2,016 EVALI patients with available data on hospitalization status, 1,906 (95%) were hospitalized, and 110 (5%) were not hospitalized. Demographic characteristics of hospitalized and nonhospitalized patients were similar; most were male (68% of hospitalized versus 65% of nonhospitalized patients), and most were aged <35 years (78% of hospitalized versus 74% of nonhospitalized patients). These patients also reported similar use of tetrahydrocannabinol (THC)-containing products (83% of hospitalized versus 84% of nonhospitalized patients). Given the similarity between hospitalized and nonhospitalized EVALI patients, the potential for large numbers of respiratory infections during the emerging 2019–20 influenza season, and the potential difficulty in distinguishing EVALI from respiratory infections, CDC will no longer collect national data on nonhospitalized EVALI patients. Further collection of data on nonhospitalized patients will be at the discretion of individual state, local, and territorial health departments. Candidates for outpatient management of EVALI should have normal oxygen saturation (≥95% while breathing room air), no respiratory distress, no comorbidities that might compromise pulmonary reserve, reliable access to care, strong social support systems, and should be able to ensure follow-up within 24–48 hours of initial evaluation and to seek medical care promptly if respiratory symptoms worsen. Health care providers should emphasize the importance of annual influenza vaccination for all persons aged ≥6 months, including persons who use e-cigarette, or vaping, products (2,3).

State health departments, the Council of State and Territorial Epidemiologists Vaping Associated Pulmonary Injury Epidemiology Task Force, and CDC developed and disseminated surveillance case definitions and data collection tools (i.e., patient interview and medical record abstraction forms) to monitor and track cases beginning in August 2019.* Some states are using these tools, whereas others elected to use state-specific tools. States and jurisdictions routinely report the number of confirmed and probable EVALI cases to CDC on a voluntary basis and, when available, include data from patient interviews and medical record abstractions. Some states have restricted case finding to hospitalized patients. Proxies (e.g., spouses or parents) were interviewed if patients were too ill or if they had died. Most states and jurisdictions report the number of cases to CDC as case status is determined; however, completing and submitting information from interviews and medical record abstraction can take up to several weeks.

This report provides updated data on patient demographic characteristics and substances used in e-cigarette, or vaping, products among hospitalized and nonhospitalized patients, as well as clinical characteristics observed among nonhospitalized patients, according to cases reported to CDC with available interview data, medical record abstraction data, or both as of November 5, 2019. Nonhospitalized EVALI patients were defined as those receiving care in an outpatient clinic, urgent care, or emergency department without report of hospitalization. Demographic and product use characteristics were compared across groups using the chi-square test, and the median ages of patients were compared using the Wilcoxon rank-sum test. SAS statistical software (version 9.4; SAS Institute) was used for the analysis.

Among 2,016 EVALI patients with available data on hospitalization status, 1,906 (95%) were hospitalized, and 110 (5%) were not hospitalized (Table 1). The nonhospitalized patients were reported from 27 states. Demographic characteristics of hospitalized and nonhospitalized patients were similar; most were male (68%; [1,228 of 1,797] of hospitalized versus 74% of nonhospitalized patients). These patients also reported similar use of THC-containing products among hospitalized and nonhospitalized patients, as well as clinical characteristics observed among nonhospitalized patients, according to cases reported to CDC with available interview data, medical record abstraction data, or both as of November 5, 2019. Nonhospitalized EVALI patients were defined as those receiving care in an outpatient clinic, urgent care, or emergency department without report of hospitalization. Demographic and product use characteristics were compared across groups using the chi-square test, and the median ages of patients were compared using the Wilcoxon rank-sum test. SAS statistical software (version 9.4; SAS Institute) was used for the analysis.

Among 2,016 EVALI patients with available data on hospitalization status, 1,906 (95%) were hospitalized, and 110 (5%) were not hospitalized (Table 1). The nonhospitalized patients were reported from 27 states. Demographic characteristics of hospitalized and nonhospitalized patients were similar; most were male (68%; [1,228 of 1,797] of hospitalized versus 74% of nonhospitalized patients). These patients also reported similar use of THC-containing products among hospitalized and nonhospitalized patients, as well as clinical characteristics observed among nonhospitalized patients, according to cases reported to CDC with available interview data, medical record abstraction data, or both as of November 5, 2019. Nonhospitalized EVALI patients were defined as those receiving care in an outpatient clinic, urgent care, or emergency department without report of hospitalization. Demographic and product use characteristics were compared across groups using the chi-square test, and the median ages of patients were compared using the Wilcoxon rank-sum test. SAS statistical software (version 9.4; SAS Institute) was used for the analysis.

* https://www.cdc.gov/tobacco/basic_information/e-cigarettes/assets/2019-Lung-Injury-Surveillance-Case-Definition-508.pdf.
[70 of 108] of nonhospitalized patients; p = 0.4) and non-Hispanic white (79% [830 of 1,048] of hospitalized versus 82% [46 of 56] of nonhospitalized patients; p = 0.5). A similar age distribution was observed: 78% (1,395 of 1,800) of hospitalized and nonhospitalized patients (p = 0.9). A higher percentage of hospitalized (55%; 1,039 of 1,896) patients compared with nonhospitalized (12%; 13 of 110) were classified with confirmed cases rather than probable cases (p<0.01). Hospitalized and nonhospitalized patients reported similar use of THC-containing products (83% [932 of 1,122] versus 84% [52 of 62], respectively; p = 0.9) and nicotine-containing products (60% [678 of 1,122] versus 73% [45 of 62], respectively; p = 0.06).

According to medical chart abstraction data reported to CDC on nonhospitalized EVALI patients’ initial outpatient medical visit, 85% (47 of 55) experienced respiratory symptoms (e.g., cough, chest pain, and shortness of breath), 57% (27 of 47) had gastrointestinal symptoms (e.g., abdominal pain, nausea, vomiting, and diarrhea), and 76% (41 of 54) had constitutional symptoms (e.g., fever, chills, and weight loss) (Table 2). Very few patients reported only one symptom type (e.g., 9% [four of 47] reported having only respiratory symptoms). Initial oxygen saturation <95% (while breathing room air) was reported among 30% (eight of 27) of patients

### TABLE 1. Demographic and e-cigarette, or vaping, product use characteristics among patients with e-cigarette, or vaping, product use–associated lung injury (EVALI) reported to CDC, by hospitalization status — United States, August–November 2019

| Characteristic                              | No./Total no. (%) | Hospitalized no./Total no. (%) | Nonhospitalized no./Total no. (%) | P-value§ |
|--------------------------------------------|-------------------|-------------------------------|----------------------------------|----------|
| **Sex**                                    |                   |                               |                                  |          |
| Male                                       | 1,298/1,905 (68)  | 1,228/1,797 (68)              | 70/108 (65)                      | 0.4      |
| Female                                     | 607/1,905 (32)    | 569/1,797 (32)                | 38/108 (35)                      |          |
| **Median age, yrs (range)**                | 24 (13–78)        | 24 (13–78)                    | 24 (15–71)                       | 0.9      |
| **Age group (yrs)**                        |                   |                               |                                  |          |
| 13–17                                      | 293/1,906 (15)    | 275/1,800 (15)                | 18/106 (17)                      |          |
| 18–24                                      | 721/1,906 (38)    | 685/1,800 (38)                | 36/106 (34)                      |          |
| 25–34                                      | 459/1,906 (24)    | 435/1,800 (24)                | 24/106 (23)                      | 0.3      |
| 35–44                                      | 256/1,906 (13)    | 242/1,800 (13)                | 14/106 (13)                      |          |
| 45–64                                      | 141/1,906 (7)     | 132/1,800 (7)                 | 9/106 (8)                        |          |
| ≥65                                         | 36/1,906 (2)      | 31/1,800 (2)                  | 5/106 (5)                        |          |
| **Race/Ethnicity¶**                        |                   |                               |                                  |          |
| White                                      | 876/1,104 (79)    | 830/1,048 (79)                | 46/56 (82)                       |          |
| Black or African American                  | 45/1,104 (4)      | 43/1,048 (4)                  | 2/56 (4)                         |          |
| American Indian or Alaska Native           | 5/1,104 (0)       | 4/1,048 (0)                   | 1/56 (2)                         |          |
| Asian, Native Hawaiian, or other           | 19/1,104 (2)      | 19/1,048 (2)                  | 0/56 (0)                         | 0.5      |
| Pacific Islander                           | 26/1,104 (2)      | 24/1,048 (2)                  | 2/56 (4)                         |          |
| Hispanic                                   | 133/1,104 (12)    | 128/1,048 (12)                | 5/56 (9)                         |          |
| **Case status**                            |                   |                               |                                  |          |
| Confirmed                                  | 1,052/2,006 (52)  | 1,039/1,896 (55)              | 13/110 (12)                      | <0.001   |
| Probable                                   | 954/2,006 (48)    | 857/1,896 (45)                | 97/110 (88)                      |          |
| **Substances used in e-cigarette, or vaping, products**†† |                   |                               |                                  |          |
| THC-containing product (any use)           | 984/1,184 (83)    | 932/1,122 (83)                | 52/62 (84)                       | 0.9      |
| Nicotine-containing product (any use)      | 723/1,184 (61)    | 678/1,122 (60)                | 45/62 (73)                       | 0.06     |
| Both THC- and nicotine-containing product use| 573/1,184 (48)   | 538/1,122 (48)                | 35/62 (56)                       |          |
| THC-containing product use only            | 411/1,184 (35)    | 394/1,122 (35)                | 17/62 (27)                       | 0.2§§    |
| Nicotine-containing product use only       | 150/1,184 (13)    | 140/1,122 (12)                | 10/62 (16)                       |          |
| No THC- or nicotine-containing product use reported | 50/1,184 (4)   | 50/1,122 (4)                  | 0/62 (0)                         |          |

Abbreviation: THC = tetrahydrocannabinol.

* For cases reported as of November 5, 2019.
† Percentages might not sum to 100% because of rounding.
§ To assess for statistically significant differences between the hospitalized and nonhospitalized patients, a chi-square test was performed for comparing categorical data and Wilcoxon rank-sum test for the comparison of the median ages.
¶ Whites, blacks or African Americans, American Indians or Alaska Natives, Asians, Native Hawaiians or other Pacific Islanders, and Others were non-Hispanic. Hispanic persons could be of any race.
** Data on both THC- and nicotine-containing product use required to be included.
†† In the 3 months preceding symptom onset.
§§ Comparison of the mutually exclusive categories of "Both THC- and nicotine-containing product use," "THC-containing product use only," "Nicotine-containing product use only," and "No THC- or nicotine-containing product use reported."
and tachycardia among 40% (10 of 25); no patients had tachypnea. Twenty-one (81%) of 26 patients with available data were reportedly prescribed corticosteroids. Among 34 patients with results reported for initial chest radiographs (CXR), 28 (82%) had abnormal findings, and 76% (19 of 25) had bilateral findings; three cases had missing information and were excluded. All 28 patients with results reported for chest computed tomography (CT) scans had abnormal findings, including 27 (96%) with bilateral findings. Six of 16 (38%) patients with information on both a CXR and chest CT had an initial normal CXR but abnormal chest CT; 10 (63%) had both an abnormal CXR and chest CT.

**Discussion**

Available data suggest that nonhospitalized EVALI patients have similar demographic and product use characteristics as do hospitalized EVALI patients. In anticipation of increasing incidence of influenza and other respiratory infections during the winter, CDC engaged with state health departments and clinical partners to assess the value of continuing to report EVALI patients who are not hospitalized. EVALI is a diagnosis of exclusion because, at present, no specific test or marker exists for its diagnosis, and evaluation should be guided by clinical judgment. Because patients with EVALI can have symptoms similar to those associated with influenza or other respiratory infections (e.g., fever, cough, headache, myalgias, or fatigue), it might be difficult to differentiate EVALI from influenza or community-acquired pneumonia on initial assessment, and EVALI might co-occur with respiratory infections. Further, continued case finding and case reporting of patients with EVALI who are treated in the outpatient setting will likely impose a significant burden on health systems and health departments during the emerging 2019–20 influenza season. Given this burden, the demographic and clinical findings from this report suggest that data from these outpatient EVALI patients likely will not provide sufficient additional evidence to the continuing investigation. Thus, CDC is no longer requesting national data on outpatient EVALI patients. Further collection of data on nonhospitalized patients will be at the discretion of individual state, local, and territorial health departments.

The findings in this report are subject to at least four limitations. First, data on substances used in e-cigarette, or vaping, products were self-reported or reported by proxies and might be subject to recall bias or social desirability bias. Therefore, underreporting might have occurred. Second, these data might be subject to misclassification of substance use for multiple reasons. Patients might not know the content of the e-cigarette, or vaping, products they used, and methods used to collect data regarding substance use varied across state. Third, data on some variables were missing for many patients, including where nonhospitalized patients received care (e.g., outpatient clinic, urgent care, or emergency department), and conclusions derived from these data might not be generalizable to the entire patient population. Finally, some states have restricted case finding to hospitalized patients, thus these data likely underestimate the actual number of nonhospitalized EVALI patients.

Candidates for outpatient management of EVALI should have normal oxygen saturation (≥95% while breathing room air), no respiratory distress, no comorbidities that might compromise pulmonary reserve, reliable access to care, strong social support systems and should be able to ensure follow-up within 24–48 hours of initial evaluation and to seek medical care promptly if respiratory symptoms worsen; in some cases, patients who initially had mild symptoms experienced a rapid worsening of symptoms within 48 hours (2,3). Health care providers should consider obtaining a chest CT scan if patients have an initial normal CXR but have symptoms and an exposure history suggestive of EVALI. Further, health care providers should consider use of antimicrobials, including
antivirals, in accordance with established guidelines. Use of corticosteroids for the treatment of EVALI in the outpatient setting should be considered with caution because it might worsen respiratory infections. Health care providers should emphasize the importance of annual influenza vaccination for all persons aged ≥6 months, including persons who use e-cigarette, or vaping, products (2,3).

Recent CDC laboratory testing has detected vitamin E acetate in bronchoalveolar lavage fluid samples from a convenience sample of 29 patients with EVALI (4). These findings provide direct evidence of vitamin E acetate at the primary site of injury within the lungs. However, evidence is not yet sufficient to rule out other chemicals of potential concern contributing to EVALI. Many different substances and product sources are still under investigation, and there might be more than one cause of this outbreak. Therefore, since the specific cause or causes of EVALI are not yet known, the only way for persons to assure that they are not at risk is to consider refraining from use of all e-cigarette, or vaping, products while this investigation continues. In particular, because most patients with EVALI report using THC-containing products before the onset of symptoms, CDC recommends that persons not use e-cigarette, or vaping, products that contain THC, especially those acquired from informal sources like friends, family members, or in-person or online dealers. Persons should not modify or add any substances to e-cigarette, or vaping, products that are not intended by the manufacturer; these include but are not limited to vitamin E acetate and other cutting agents and additives obtained from informal sources or purchased through retail establishments. Irrespective of the ongoing investigation, e-cigarette, or vaping, products should never be used by youths, young adults, or women who are pregnant. Moreover, persons who do not currently use tobacco products should not start using e-cigarette, or vaping, products (2). Adults using e-cigarette, or vaping, products to quit smoking should not return to smoking cigarettes; they should weigh all risks and benefits and consider using FDA-approved cessation medications. Adults who continue to use e-cigarette, or vaping, products should carefully monitor themselves for symptoms and see a health care provider immediately if they develop symptoms like those reported in this outbreak.

1 https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/index.html?s_cid.

Acknowledgments

Sarah Khalidi, Sondra Reese, Alabama Department of Public Health; Emily M. Carlson, Tiana Galindo, Arizona Department of Health Services; Appathurai Balamurugan, Allison James, Brandy Sutphin, Arkansas Department of Health; Ellora Karmarkar, Svetlana Smorodinsky, California Department of Public Health; Elyse Contreras, Katelyn E. Hall, Colorado Department of Public Health and Environment; Sydney Jones, Jaime Krasnitski, Connecticut Department of Public Health; Amanda Bundek, Caroline Judd, Delaware Department of Health and Social Services, Division of Public Health; Adrienne Sherman, Kenan Zamore, District of Columbia Department of Health; Heather Rubino, Thomas Troelstrup, Florida Department of Health; Georgia Department of Public Health Lung Injury Response Team; Hawaii Department of Health; Eileen M. Dunne, Kathryn A. Tuer, Idaho Division of Public Health; Dawn Nims, Lori Saathoff-Huber, Illinois Department of Public Health; Sara Hallyburton, Kathryn Gaub, Charles R. Clark, Indiana State Department of Health; Chris Galeazzi, Rob Ramaekers, Iowa Department of Public Health; Amie Cook, Justin Blanding, Kansas Department of Health and Environment; Kentucky Department for Public Health; Louisiana Department of Health; Maine Center for Disease Control and Prevention; Kenneth A. Feder, Clifford S. Mitchell, Maryland Department of Health; Daniel Church, MaryKate Martelon, Massachusetts Department of Public Health; Rita Seith, Eden V. Wells, Michigan Department of Health and Human Services; Stacy Holzbauer, Terra Wiens, Minnesota Department of Health; Paul Byers, Kathryn Taylor, Mississippi State Department of Health; Valerie Howard, George Turabelidze, Missouri Department of Health and Senior Services; Isaiah Reid, Montana Department of Public Health and Human Services; Matthew Donahue, Tom Safranek, Nebraska Department of Health and Human Services; Ashleigh Faulstich, Victoria LeGarde, Melissa Peek-Bullock, Nevada Department of Health and Human Services; Pascal Kalin, Suzann Beauregard, New Hampshire Department of Health and Human Services; Stephen Perez, Lisa McHugh, New Jersey Department of Health; Alex Gallegos, Joseph T. Hicks, New Mexico Department of Health; Adam Helman, Kristen Navarette, New York State Department of Health; Dana Dandeneau, Kendall Knuth, North Carolina Division of Public Health; Tracy Miller, Kodi Pinks, North Dakota Department of Health; Courtney Dewart, Kirtana Ramadugu, Ohio Department of Health; Claire B. Nguyen, Tracy Wendling, Oklahoma State Department of Health; Amanda Faulkner, Tasha Poissant, Oregon Health Authority; Barry Miller, Laurel Harduar Morano, Pennsylvania Department of Health;
Ailis Clyne, Morgan Orr, James Rajotte, Rhode Island Department of Health; Sharon Biggers, Virginie Daguise, Daniel Kilpatrick, South Carolina Department of Health & Environmental Control; Joshua L. Clayton, Jonathan Steinberg, South Dakota Department of Health; Kelly Squires, Julie Shaffner, Tennessee Department of Health; Emily Hall, Varun Shetty, Texas Department of State Health Services; Esther M. Ellis, US Virgin Islands Department of Health; Deanna Ferrell, Jordan Green, Nathaniel Lewis, Keegan McCaffrey, Utah Department of Health; Julia Brennan, Vermont Department of Health; Jonathan Falk, Lilian Peake, Virginia Department of Health; Melanie Payne, Cathy Wasserman, Washington State Department of Health; Shannon McBee, Christy Reed, West Virginia Department of Health and Human Resources; Jonathan Meiman, Ian Pray, Wisconsin Department of Health Services; Melissa Taylor, Wyoming Department of Health.

**Lung Injury Response Epidemiology/Surveillance Task Force**

Kayla Anderson, National Center on Birth Defects and Developmental Disabilities, CDC; Francis B. Annor, National Center for Injury Prevention and Control, CDC; Sharyn E. Brown, National Center for Chronic Disease Prevention and Health Promotion, CDC; Angela D. Coulllette-Salmond, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Kristen N. Cowan, National Center for Environmental Health, CDC; Angela Dunn, Utah Department of Health; Aaron Fleishauer, North Carolina Department of Health and Human Services; Jennifer Freed, Agency for Toxic Substances and Disease Registry; Macarena C. Garcia, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Janet Hamilton, Council of State and Territorial Epidemiologists; Donald Hayes, National Center for Chronic Disease Prevention and Health Promotion, CDC; Michelle M. Hughes, National Center on Birth Defects and Developmental Disabilities, CDC; Mia Israel, Council of State and Territorial Epidemiologists; Anne Kimball, Epidemic Intelligence Service, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; Hannah Kisselburgh, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Jennifer Layden, Illinois Department of Public Health; Akaki Lekiachvili, National Center for Chronic Disease Prevention and Health Promotion, CDC; Matthew Lozier, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Ruth Lynfield, Minnesota Department of Health; Jonathan Meiman, Wisconsin Department of Health; Erin D. Moritz, National Center for Environmental Health, CDC; Rashid Njai, National Center for Chronic Disease Prevention and Health Promotion, CDC; Jeffrey Ratto, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Sarah L. Shafer, National Center for Immunization and Respiratory Diseases, CDC; Stephen Soroka, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Natalie Sterrett, National Center for Immunization and Respiratory Diseases, CDC; Kimberly R. Thomas, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Bailey Wallace, National Center on Birth Defects and Developmental Disabilities, CDC; Angela K. Werner, National Center for Environmental Health, CDC; Jason Wilken, California Department of Public Health; Lauren B. Zapata, National Center for Chronic Disease Prevention and Health Promotion, CDC.

**Lung Injury Response Clinical Task Force**

Susan Hocevar Adkins, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; Emily A. Kiernan, Agency for Toxic Substances and Disease Registry; Ram Koppaka, National Center for Immunization and Respiratory Diseases, CDC; Emily H. Koumans, National Center for Chronic Disease Prevention and Health Promotion, CDC; Mark Layer, National Center for Environmental Health, CDC; Jaswinder Legha, National Center for Injury Prevention and Control, CDC; Michelle Montandon, Center for Global Health, CDC; Sarah Reagan-Steiner, National Center for Emerging and Zoonotic Infectious Diseases, CDC; David A. Siegel, National Center for Chronic Disease Prevention and Health Promotion, CDC; David N. Weissman, National Institute for Occupational Safety and Health, CDC; Jennifer L. Wiltz, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Corresponding author: Kevin Chatham-Stephens, kchathamstephens@cdc.gov

1National Center on Birth Defects and Developmental Disabilities, CDC; 2National Center for Emerging and Zoonotic Infectious Diseases, CDC; 3National Center for Immunization and Respiratory Disease, CDC; 4National Center for Chronic Disease Prevention and Health Promotion, CDC; 5National Center for Environmental Health, CDC; 6National Center for Injury Prevention and Control, CDC; 7National Institute for Occupational Safety and Health, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

**References**

1. Moritz ED, Zapata LB, Lekiachvili A, et al.; Lung Injury Response Epidemiology/Surveillance Group; Lung Injury Response Epidemiology/Surveillance Task Force. Update: characteristics of patients in a national outbreak of e-cigarette, or vaping, product use–associated lung injuries—United States, October 2019. MMWR Morb Mortal Wkly Rep 2019;68:919–27. https://doi.org/10.15585/mmwr.mm6845e2

2. Siegel DA, Jatlaoui TC, Koumans EH, et al.; Lung Injury Response Clinical Working Group: Lung Injury Response Epidemiology/Surveillance Group. Update: interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use–associated lung injury. MMWR Morb Mortal Wkly Rep 2019;68:919–27. https://doi.org/10.15585/mmwr.mm6846e1

3. Jatlaoui TC, Wiltz JL, Kabhani S, et al. Update: interim guidance for health care providers regarding the management approach of patients with suspected e-cigarette, or vaping, product use–associated lung injury—United States, November 2019. MMWR Morb Mortal Wkly Rep 2019;68:46(46).

4. Blount BC, Karwowski MP, Morel-Espinosa M, et al. Evaluation of bronchoalveolar lavage fluid from patients in an outbreak of e-cigarette, or vaping, product use–associated lung injury—10 states, August–October 2019. MMWR Morb Mortal Wkly Rep 2019;68:1040–1. https://doi.org/10.15585/mmwr.mm6845c2